BILLERICA, Mass. - Bruker (NASDAQ:BRKR) Corporation (NASDAQ:BRKR) has announced the formation of Bruker Spatial Biology, a new division aimed at advancing biomedical research through a suite of spatial biology instruments, assays, software, data analytics, and contract research organization (CRO) services. The division consolidates the technologies and services of NanoString Technologies, Canopy Biosciences, and Bruker Spatial Genomics, Inc., previously known as Acuity Spatial Genomics, Inc.
The newly formed division is poised to offer a diverse set of spatial biology research tools, including NanoString's GeoMx®, CosMx™, and AtoMx™ platforms, along with Canopy Biosciences' CellScape™. These platforms are tailored to meet various research needs in spatial genomics, transcriptomics, and proteomics. Additionally, NanoString's nCounter® for gene expression analysis and Canopy's Multi-Omic Services are included in the comprehensive portfolio.
Mark R. Munch, PhD, President of the Bruker NANO group, emphasized the strategic coordination of best-in-class spatial platforms that the new division represents. He highlighted the direct visualization capabilities of the 3D genome offered by Bruker Spatial Genomics, which complements the high sensitivity and resolution of the GeoMx and CosMx tools for spatial transcriptomics.
Todd Garland, President of Bruker Spatial Biology, expressed enthusiasm for leading the division, noting the ability to provide customized solutions for global research customers. The division's approach is designed to avoid a "one-size-fits-all" methodology, instead offering tailored solutions across the entire research spectrum.
Bruker Spatial Biology will be demonstrating its technologies at the Society for Immunotherapy of Cancer (SITC) 2024, to be held from November 8-10 in Houston, Texas.
Bruker Corporation, known for its contributions to the post-genomic era, develops high-performance instruments and analytical solutions for life sciences, biopharma, microscopy, nanoanalysis, industrial research, and semiconductor metrology. The company's systems are integral to various fields, including preclinical imaging, clinical phenomics, proteomics, multiomics, spatial and single-cell biology, functional structural biology, clinical microbiology, and molecular diagnostics.
This news article is based on a press release statement from Bruker Corporation.
In other recent news, Bruker Corporation reported a substantial 17.4% increase in Q2 revenues, totaling $800.7 million, and a 4.5% organic revenue growth for the first half of the year, leading to total revenues of $1.52 billion. The company maintains its full-year guidance of 5% to 7% organic revenue growth. Amid these developments, Bruker has acquired Dynamic Biosensors GmbH, a biosensor technology company, aiming to enhance its biophysical portfolio for molecular interaction analysis. Analysts' reactions to Bruker's recent performance and future prospects have varied. While Citi and TD Cowen have reiterated their Buy and Hold ratings, respectively, Wolfe Research has downgraded Bruker shares from Outperform to Peer Perform, citing concerns about Bruker's financial outlook and the pace of improvement in demand for the company's instruments. These are some of the recent developments in Bruker Corporation.
InvestingPro Insights
Bruker Corporation's (NASDAQ:BRKR) strategic move to form Bruker Spatial Biology aligns with its strong financial performance and market position. According to InvestingPro data, the company boasts a market capitalization of $9.65 billion and has demonstrated robust revenue growth, with a 14.93% increase in the last twelve months as of Q2 2024. This growth trajectory supports the company's expansion into the spatial biology market.
InvestingPro Tips highlight that Bruker has been profitable over the last twelve months and analysts predict continued profitability this year. This financial stability provides a solid foundation for the company's new division and its ambitious plans in the spatial biology sector.
However, investors should note that Bruker is trading at a high P/E ratio of 29.69 (adjusted for the last twelve months as of Q2 2024) relative to its near-term earnings growth. This valuation suggests that the market has high expectations for the company's future performance, including potential contributions from the new Spatial Biology division.
For those interested in a deeper analysis, InvestingPro offers 7 additional tips for Bruker Corporation, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.